Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published 15 May 2007 Volume 2007:3(2) Pages 237—243

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Comparison of bone tissue trace-element concentrations and mineral density in osteoporotic femoral neck fractures and osteoarthritis

Karaaslan F, Mutlu M, Mermerkaya MU, Karaoğlu S, Saçmaci Ş, Kartal Ş

Clinical Interventions in Aging 2014, 9:1375-1382

Published Date: 18 August 2014

Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model

Yuan L, Liu CY, Chen Y, Zhang ZH, Zhou L, Qu D

International Journal of Nanomedicine 2013, 8:4339-4350

Published Date: 5 November 2013

The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation

Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q

International Journal of Nanomedicine 2013, 8:2473-2485

Published Date: 15 July 2013

Multilayer bioactive glass/zirconium titanate thin films in bone tissue engineering and regenerative dentistry

Mozafari M, Salahinejad E, Shabafrooz V, Yazdimamaghani M, Vashaee D, Tayebi L

International Journal of Nanomedicine 2013, 8:1665-1672

Published Date: 26 April 2013

Few-layer graphene sheets with embedded gold nanoparticles for electrochemical analysis of adenine

Biris AR, Pruneanu S, Pogacean F, Lazar MD, Borodi G, Ardelean S, Dervishi E, Watanabe F, Biris AS

International Journal of Nanomedicine 2013, 8:1429-1438

Published Date: 12 April 2013

Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles

Dhanasooraj D, Kumar RA, Mundayoor S

International Journal of Nanomedicine 2013, 8:835-843

Published Date: 25 February 2013